THE November 21, 2024, Accure Acne, Inc. will stand out at the conference Medtech, Diagnostics, and Digital Health & Services organized by Canaccord Genuity has new York. This presentation will highlight the company’s advances in the treatment of acne, including its successful commercial launch in the United States and the recent obtaining of a FDA approval for a device intended to treatinflammatory acne. Members of the management team will meet to discuss progress and future prospects, while providing opportunities for one-on-one meetings with investors.
Accure Acne, Inc. announced that she will present at the conference Medtech, Diagnostics, and Digital Health & Services organized by Canaccord Genuity. The presentation will take place on November 21, 2024 has new York, at 9:00 a.m. (EST). Company leaders, including Christopher Carlton And Vlad Paul-Blanc, will discuss the successful completion of their limited commercial launch in the United States, expansion into key markets and recent receipt of re-authorization from the FDA for long-term treatment of inflammatory acne of mild to severe severity.
One-on-one meetings with investors will also be possible during the conference, with event attendees encouraged to get in touch for in-depth discussions.
Accure Acne, Inc. and Canaccord Genuity Medtech Event
As part of their commitment to innovation in acne treatment, Accure Acne, Inc. will announce a presentation at the annual conference organized by Canaccord Genuity, on the subjects of technical medicine, of diagnosis and digital services. This event will take place on November 21, 2024, has New York City, at 9:00 a.m. Eastern Time. Key members of the management team, including CEO Christopher Carlton And Vlad Paul-Blanc, will meet to discuss the latest advances in the company.
Launch of innovative solutions against acne
Accure has indeed developed revolutionary solutions, including Accure laser system, recognized as the first system based on technology 1726nm to have received both the marking THIS and authorization of the FDA. This presentation will be an opportunity to share significant results, including the reception downstream for long-term treatment of inflammatory acne, ranging from mild to severe type. Attendees will learn about the company’s continued expansion into key markets around the world.
Personalized meetings for investors
In addition to the presentation, Accure management will be available for individual meetings with the investors present. This dialogue not only allows us to discuss the company’s future plans, but also to answer questions from investors interested in advances in the field of digital health. This is an opportunity for anyone interested in learning more about the innovations Accure offers and the significant impact they will have on global acne care.
